JPS55141407A - Nonoral administration solution containing arylacetic acid or arylpropionic acid derivative - Google Patents

Nonoral administration solution containing arylacetic acid or arylpropionic acid derivative

Info

Publication number
JPS55141407A
JPS55141407A JP4632180A JP4632180A JPS55141407A JP S55141407 A JPS55141407 A JP S55141407A JP 4632180 A JP4632180 A JP 4632180A JP 4632180 A JP4632180 A JP 4632180A JP S55141407 A JPS55141407 A JP S55141407A
Authority
JP
Japan
Prior art keywords
solution containing
acid
administration solution
arylacetic
arylpropionic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP4632180A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0337524B2 (en:Method
Inventor
Gitsuchi Mikurosu
Ritsutsuman Getsutsu
Erudesu Adorujiyan
Etsushienberuku Oigen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Natterman und Cie GmbH
Original Assignee
A Natterman und Cie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Natterman und Cie GmbH filed Critical A Natterman und Cie GmbH
Publication of JPS55141407A publication Critical patent/JPS55141407A/ja
Publication of JPH0337524B2 publication Critical patent/JPH0337524B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP4632180A 1979-04-11 1980-04-10 Nonoral administration solution containing arylacetic acid or arylpropionic acid derivative Granted JPS55141407A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792914788 DE2914788A1 (de) 1979-04-11 1979-04-11 Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung

Publications (2)

Publication Number Publication Date
JPS55141407A true JPS55141407A (en) 1980-11-05
JPH0337524B2 JPH0337524B2 (en:Method) 1991-06-05

Family

ID=6068137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4632180A Granted JPS55141407A (en) 1979-04-11 1980-04-10 Nonoral administration solution containing arylacetic acid or arylpropionic acid derivative

Country Status (14)

Country Link
US (1) US4309421A (en:Method)
JP (1) JPS55141407A (en:Method)
AT (1) AT369651B (en:Method)
AU (1) AU539044B2 (en:Method)
BE (1) BE882731A (en:Method)
CA (1) CA1144480A (en:Method)
CH (1) CH642546A5 (en:Method)
DE (1) DE2914788A1 (en:Method)
FR (1) FR2453644B1 (en:Method)
GB (1) GB2046094B (en:Method)
IT (1) IT1148790B (en:Method)
NL (1) NL8002097A (en:Method)
SE (1) SE451427B (en:Method)
ZA (1) ZA802157B (en:Method)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203011A (en) * 1981-06-05 1982-12-13 Taiyo Yakuhin Kogyo Kk Anti-inflammatory external agent
JPS63192716A (ja) * 1987-01-30 1988-08-10 チバーガイギー　アクチェンゲゼルシャフト 非経口投与用懸濁液
JP2004517037A (ja) * 2000-06-23 2004-06-10 メデイノックス，インコーポレイテッド 修飾された形の薬理活性薬物およびそれらの用途
US6974593B2 (en) 1995-10-17 2005-12-13 Jagotec Ag Insoluble drug delivery

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042365C2 (de) * 1980-11-10 1987-01-29 Extrakta Strauss GmbH, 2000 Hamburg Flüssige, lecithinhaltige einphasige Mehrstoffsysteme und Verfahren zu ihrer Herstellung
EP0146243A1 (en) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
DE3346526C2 (de) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
DE3346525C2 (de) * 1983-12-22 1987-03-19 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-glycero-3-phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US5171566A (en) * 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
DE3621036A1 (de) * 1986-06-24 1988-01-07 Merckle Gmbh Fluessige ibuprofen-zubereitungen
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DE4124252A1 (de) * 1991-07-22 1993-01-28 Knoll Ag Verfahren zur herstellung einer sterilfiltrierbaren wirkstoffloesung
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
DE4305003A1 (de) * 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
ATE218872T1 (de) * 1995-01-27 2002-06-15 Univ Texas Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
AU762246B2 (en) * 1998-02-11 2003-06-19 Rtp Pharma Corporation Method and composition for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
HK1039458B (zh) 1998-05-29 2006-09-01 Skyepharma Canada Inc. 熱保護微粒組合物及其最終蒸汽滅菌的方法
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
HK1040195B (zh) 1998-08-19 2006-06-02 Skyepharma Canada Inc. 普鲁泊福的可注射水分散体
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
AU767154B2 (en) 1998-11-20 2003-10-30 Skyepharma Canada Inc. Dispersible phospholipid stabilized microparticles
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
EP1276465B1 (en) 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
ES2372746T3 (es) * 2000-09-20 2012-01-26 Jagotec Ag Micropartículas de fibrato estabilizadas.
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
AU2001259099B2 (en) * 2001-02-22 2005-12-22 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US20040132823A1 (en) * 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
CA2534241C (en) 2003-07-31 2012-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
EP1983983A4 (en) * 2006-02-06 2009-11-25 Pharmaceutical Solutions Inc NON-STEROIDAL, ANTI-FLAMMATORALLY ACTIVE ORAL POWDER AND LIQUID PREPARATIONS FOR ADMINISTRATION IN ANIMALS
WO2008013822A2 (en) * 2006-07-26 2008-01-31 The Board Of Regent Of The University Of Texas System Parenteral preparations of gi-safer phospholipid-associated anti-inflammatories and methods of preparation and use
WO2010105129A1 (en) 2009-03-12 2010-09-16 Cumberland Pharmaceuticals Administration of intravenous ibuprofen
US8871810B2 (en) 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US8735452B2 (en) * 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
KR20120089444A (ko) * 2009-07-31 2012-08-10 큠버랜드 파마슈티컬즈 인코포레이티드 정맥내 이부프로펜에 의한 위독한 환자의 치료방법
FR2971712B1 (fr) * 2011-02-22 2016-06-10 Map France Solution stable de ketoprofene pour injection intraveineuse
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
PE20150083A1 (es) 2012-03-16 2015-01-21 Cumberland Pharmaceuticals Inc Formulacion de ibuprofeno inyectable
US9072661B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
ES2955693T3 (es) 2012-12-24 2023-12-05 Neurogastrx Inc Métodos para el tratamiento de trastornos del tracto GI
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52143218A (en) * 1976-03-19 1977-11-29 Ici Ltd Pharmaceutical composition
JPS6320209A (ja) * 1986-07-11 1988-01-27 Mitsubishi Motors Corp 油圧サスペンシヨン装置を備える車両の車高調整方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3044931A (en) * 1960-01-27 1962-07-17 Geigy Chem Corp Aryloxy acetic acid amides: process for parenteral application
CA725596A (en) * 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
IT1202370B (it) * 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
DE2856333C2 (de) * 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52143218A (en) * 1976-03-19 1977-11-29 Ici Ltd Pharmaceutical composition
JPS6320209A (ja) * 1986-07-11 1988-01-27 Mitsubishi Motors Corp 油圧サスペンシヨン装置を備える車両の車高調整方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203011A (en) * 1981-06-05 1982-12-13 Taiyo Yakuhin Kogyo Kk Anti-inflammatory external agent
JPS63192716A (ja) * 1987-01-30 1988-08-10 チバーガイギー　アクチェンゲゼルシャフト 非経口投与用懸濁液
US6974593B2 (en) 1995-10-17 2005-12-13 Jagotec Ag Insoluble drug delivery
JP2004517037A (ja) * 2000-06-23 2004-06-10 メデイノックス，インコーポレイテッド 修飾された形の薬理活性薬物およびそれらの用途

Also Published As

Publication number Publication date
CA1144480A (en) 1983-04-12
JPH0337524B2 (en:Method) 1991-06-05
GB2046094A (en) 1980-11-12
ZA802157B (en) 1981-05-27
AU539044B2 (en) 1984-09-06
IT1148790B (it) 1986-12-03
SE8002714L (sv) 1980-10-12
ATA195880A (de) 1982-06-15
AU5733180A (en) 1980-10-16
SE451427B (sv) 1987-10-12
US4309421A (en) 1982-01-05
IT8021299A0 (it) 1980-04-10
DE2914788A1 (de) 1980-10-16
AT369651B (de) 1983-01-25
NL8002097A (nl) 1980-10-14
BE882731A (fr) 1980-07-31
GB2046094B (en) 1983-10-26
FR2453644A1 (fr) 1980-11-07
CH642546A5 (de) 1984-04-30
FR2453644B1 (fr) 1985-07-05
DE2914788C2 (en:Method) 1990-06-21

Similar Documents

Publication Publication Date Title
JPS55141407A (en) Nonoral administration solution containing arylacetic acid or arylpropionic acid derivative
PT71744A (en) Substituted beta-carbolin-3-carboxylic acid derivatives
JPS5625146A (en) 33aminopropanesulfonic acid derivative
GB2046730B (en) Epoxysuccinic acid derivatives
JPS5726641A (en) Use of substituted derivative of 4-phenyl-4-oxo-2-butenoic acid as drug
ZA801016B (en) Mercaptoacyldihydropyrazole carboxylic acid derivatives
GB2117774B (en) Oximinoacetic acid derivatives
JPS54157817A (en) Pharmaceutical prepared solution
AU533471B2 (en) Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid
JPS55147262A (en) 22hydroxyy55*11hydroxyy22piperazinylethyl*benzoic acid derivative
GB2025397B (en) Arylacetic acid derivatives
JPS5612365A (en) Mercaptoacylamino acid derivative
JPS5677262A (en) Mercaptoacyldihydropyrazolecarboxylic acid derivative
IL55152A0 (en) 7-acylamido-3-cephem-4-carboxylic acids and esters and salts thereof,their preparation and pharmaceutical compositions containing them
AU542860B2 (en) Pharmaceutical carovering salts
JPS56167636A (en) Use of 4-phenyl-4-oxy-2-hydroxybutanoic acid substitution derivative as drug
ZA818370B (en) N-pyrimidinyl-carbamic acid esters, their preparation, and drugs containing these compounds
AU535357B2 (en) Stable pharmaceutical solution
GB2053912B (en) Acylaminobenzoic acid derivatives
GB2045233B (en) Unsaturated 3-heterocyclylthiomethyl-7a-methoxy-7-acylamido-3-cephem-4-carboxylic acid derivatives
JPS5659742A (en) Nnacyllamino acid derivative
NZ182807A (en) Pharmaceutical compsoitions containing benzoic acid derivatives
ZA803734B (en) Acylaminobenzoic acid derivatives
JPS5615269A (en) Dihydronicotinic acid derivative
GB2125035B (en) 6b-halopenicillanic acid derivatives